10x Genomics announced that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3′ v4 and Chromium Single Cell Immune Profiling 5′ v3. GEM-X is the next generation of the company’s leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- Cathie Wood’s ARK Investment bought 157K shares of 10x Genomics today
- 10x Genomics price target lowered to $63 from $68 at Stifel
- 10x Genomics price target lowered to $65 from $70 at Canaccord
- 10x Genomics sees FY23 revenue $670M-$690M, consensus $702.06M
- 10x Genomics reports Q4 EPS (41c), consensus (36c)